Immunocore reports 70% two-year overall survival for brenetafusp/KIMMTRAK combination in uveal melanoma

Immunocore presented positive Phase 1/2 data for the combination of brenetafusp and KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma. In 17 first-line patients, the estimated two-year overall survival rate was 70%, with median overall survival not yet reached at a median follow-up of 29 months.

Detected & updated continuously · Source: Nebula